Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-BID Antibody-FITC (9U548) is a FITC-conjugated Mouse antibody targeting BID. Anti-BID Antibody-FITC (9U548) can be used in FCM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 T | $105 | 7-10 days | |
100 T | $211 | 7-10 days |
Description | Antibody Type: Mouse Monoclonal Application: FCM Reactivity: Human |
Alias | BH3 interacting domain death agonist, AU022477, AI875481, 2700049M22Rik |
Ig Type | Mouse IgG1 |
Clone | 9U548 |
Reactivity | Human |
Verified Activity | Flow cytometric analysis of BID expression on Jurkat cells. The cells were treated according to manufacturer’s manual (BD Pharmingen™ Cat. No. 554714), and then stained with FITC Mouse anti-BID. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells. |
Application | FCM |
Recommended Dose | 10 μl/Test, 0.1 mg/ml |
Antibody Type | Monoclonal |
Host Species | Mouse |
Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human BID (rh BID; TMPY-02027; P55957-1; Met 1-Asp 195) and conjugated with FITC under optimum conditions, the unreacted FITC was removed. |
Purification | Protein A |
Appearance | Liquid |
Formulation | PBS solution containing 0.5% BSA and 0.09% sodium azide |
Research Background | The BH3 interacting domain death agonist (BID) is a pro-apoptotic member of the Bcl-2 protein family, which contains only the BH3 domain, and is required for its interaction with the Bcl-2 family proteins and for its pro-death activity. BID is important to cell death mediated by these proteases and thus is the sentinel to protease-mediated death signals. Recent studies further indicate that Bid may be more than just a killer molecule, it could be also involved in the maintenance of genomic stability by engaging at mitosis checkpoint. BID is an integrating key regulator of the intrinsic death pathway that amplifies caspase-dependent and caspase-independent execution of neuronal apoptosis. Therefore pharmacological inhibition of BID provides a promising therapeutic strategy in neurological diseases where programmed cell death is prominent. BID is activated by Caspase 8 in response to Fas/TNF-R1 death receptor activation. Activated BID is translocated to mitochondria and induces cytochrome c release, which in turn activates downstream caspases. BID action has been proposed to involve the mitochondrial re-location of its truncated form, tBid, to facilitate the release of apoptogenic proteins like cytochrome c. |
Conjucates | FITC |
Others Formats | Unconjugated |
Antibody Types Available | 2 |
Immunogen | Recombinant Protein: Human BID protein (TMPY-02027) |
Antigen Species | Human |
Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.